Janux Therapeutics (JANX) Change in Accured Expenses (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Change in Accured Expenses data on file, last reported at -$2.0 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 217.07% year-over-year to -$2.0 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 67.33% decrease from a year earlier, with the FY2025 full-year figure at $6.3 million, up 42.11% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.0 million, up from -$4.5 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for JANX reached as high as $6.2 million in Q3 2025 and fell as low as -$4.5 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $715529.4 across 5 years, with a median of $1.0 million in 2022.
• Across the five-year window, Change in Accured Expenses surged 605.87% in 2022 and sank 483.57% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.0 million in 2022, then slumped by 57.61% to $426000.0 in 2023, then sank by 483.57% to -$1.6 million in 2024, then slumped by 176.38% to -$4.5 million in 2025, then jumped by 55.05% to -$2.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$2.0 million in Q1 2026, -$4.5 million in Q4 2025, and $6.2 million in Q3 2025.